| [1] |
|
| [2] |
Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024[J]. CA A Cancer J Clinicians, 2024, 74(1): 12-49. DOI: 10.3322/caac.21820.
|
| [3] |
Petrau C, Cornic M, Bertrand P, et al. CD70: a potential target in breast cancer?[J]. J Cancer, 2014, 5(9): 761-764. DOI: 10.7150/jca.10360.
|
| [4] |
Jin L, Ge H, Long Y, et al. CD70, a novel target of CAR T-cell therapy for gliomas[J]. Neuro-Oncology, 2018, 20(1): 55-65. DOI: 10.1093/neuonc/nox116.
|
| [5] |
Liu N, Sheng X, Liu Y, et al. Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas[J]. Onco Targets Ther, 2013, 6: 615-619. DOI: 10.2147/OTT.S44445.
|
| [6] |
Huang RR, Chen Z, Kroeger N, et al. CD70 is consistently expressed in primary and metastatic clear cell renal cell carcinoma[J]. Clin Genitourin Cancer, 2024, 22(2): 347-353. DOI: 10.1016/j.clgc.2023.12.003.
|
| [7] |
Boursalian TE, McEarchern JA, Law CL, et al. Targeting CD70 for human therapeutic use[J]. Adv Exp Med Biol, 2009, 647: 108-119. DOI: 10.1007/978-0-387-89520-8_7.
|
| [8] |
Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. The CD70-CD27 axis in oncology: the new kids on the block[J]. J Exp Clin Cancer Res, 2022, 41(1): 12. DOI: 10.1186/s13046-021-02215-y.
|
| [9] |
Benhamouda N, Sam I, Epaillard N, et al. Plasma CD27, a surrogate of the intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cell carcinoma[J]. Clin Cancer Res, 2022, 28(22): 4983-4994. DOI: 10.1158/1078-0432.CCR-22-0905.
|
| [10] |
Ruf M, Mittmann C, Nowicka AM, et al. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27 + lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma[J]. Clin Cancer Res, 2015, 21(4): 889-898. DOI: 10.1158/1078-0432.CCR-14-1425.
|
| [11] |
Aboagye EO, Barwick TD, Haberkorn U. Radiotheranostics in oncology: making precision medicine possible[J]. CA Cancer J Clin, 2023, 73(3): 255-274. DOI: 10.3322/caac.21768.
|
| [12] |
Wei W, Younis MH, Lan X, et al. Single-domain antibody theranostics on the horizon[J]. J Nucl Med, 2022, 63(10): 1475-1479. DOI: 10.2967/jnumed.122.263907.
|
| [13] |
Krasniqi A, D'Huyvetter M, Devoogdt N, et al. Same-day imaging using small proteins: clinical experience and translational prospects in oncology[J]. J Nucl Med, 2018, 59(6): 885-891. DOI: 10.2967/jnumed.117.199901.
|
| [14] |
Cleeren F, Lecina J, Bridoux J, et al. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method[J]. Nat Protoc, 2018, 13(10): 2330-2347. DOI: 10.1038/s41596-018-0040-7.
|
| [15] |
Qin X, Guo X, Liu T, et al. High in-vivo stability in preclinical and first-in-human experiments with [ 18F] AlF-RESCA-MIRC213: a 18F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers[J]. Eur J Nucl Med Mol Imaging, 2023, 50(2): 302-313. DOI: 10.1007/s00259-022-05967-7.
|
| [16] |
Wang C, Chen Y, Hou YN, et al. ImmunoPET imaging of multiple myeloma with [ 68Ga] Ga-NOTA-Nb1053[J]. Eur J Nucl Med Mol Imag, 2021, 48(9): 2749-2760. DOI: 10.1007/s00259-021-05218-1.
|
| [17] |
Wu Q, Wu Y, Zhang Y, et al. ImmunoPET/CT imaging of clear cell renal cell carcinoma with [18F] RCCB6: a first-in-human study[J]. Eur J Nucl Med Mol Imag, 2024, 51(8): 2444-2457. DOI: 10.1007/s00259-024-06672-3.
|
| [18] |
Gelardi F, Larcher A, Antunovic L, et al. Biological characterization of renal masses using immuno-PET[J]. Eur J Nucl Med Mol Imaging, 2024, 51(8): 2442-2443. DOI: 10.1007/s00259-024-06757-z.
|
| [19] |
Wu Q, Wu Y, Zhang Y, et al. [ 18F] RCCB6 immuno-positron emission tomography/computed tomography for postoperative surveillance in clear cell renal cell carcinoma: a pilot clinical study[J]. Eur Urol, 2024, 86(4): 372-374. DOI: 10.1016/j.eururo.2024.06.020.
|
| [20] |
Riether C, Pabst T, Höpner S, et al. Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents[J]. Nat Med, 2020, 26(9): 1459-1467. DOI: 10.1038/s41591-020-0910-8.
|
| [21] |
Tannir NM, Forero-Torres A, Ramchandren R, et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma[J]. Invest New Drugs, 2014, 32(6): 1246-1257. DOI: 10.1007/s10637-014-0151-0.
|
| [22] |
Pal SK, Forero-Torres A, Thompson JA, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma[J]. Cancer, 2019, 125(7): 1124-1132. DOI: 10.1002/cncr.31912.
|
| [23] |
Li S, Chen D, Guo H, et al. The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70/CD27 signaling[J]. Front Oncol, 2023, 13: 1240061. DOI: 10.3389/fonc.2023.1240061.
|
| [24] |
Yang M, Tang X, Zhang Z, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors[J]. Theranostics, 2020, 10(17): 7622-7634. DOI: 10.7150/thno.43991.
|
| [25] |
Xiong Q, Wang H, Shen Q, et al. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment[J]. J Transl Med, 2024, 22(1): 368. DOI: 10.1186/s12967-024-05101-1.
|
| [26] |
Ji F, Zhang F, Zhang M, et al. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway[J]. J Hematol Oncol, 2021, 14(1): 152. DOI: 10.1186/s13045-021-01168-1.
|
| [27] |
Panowski SH, Srinivasan S, Tan N, et al. Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma[J]. Cancer Res, 2022, 82(14): 2610-2624. DOI: 10.1158/0008-5472.CAN-21-2931.
|
| [28] |
Pal SK, Tran B, Haanen JBAG, et al. CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma[J]. Cancer Discov, 2024, 14(7): 1176-1189. DOI: 10.1158/2159-8290.CD-24-0102.
|
| [29] |
Nagato T, Komatsuda H, Hayashi R, et al. Soluble CD27 as a predictive biomarker for intra-tumoral CD70/CD27 interaction in nasopharyngeal carcinoma[J]. Cancer Sci, 2024, 115(4): 1073-1084. DOI: 10.1111/cas.16079.
|
| [30] |
Świderska J, Kozłowski M, Gaur M, et al. Clinical significance of BTLA, CD27, CD70, CD28 and CD80 as diagnostic and prognostic markers in ovarian cancer[J]. Diagnostics (Basel), 2022, 12(2): 251. DOI: 10.3390/diagnostics12020251.
|
| [31] |
Massard C, Soria JC, Krauss J, et al. First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed/refractory renal cell carcinoma[J]. Cancer Chemother Pharmacol, 2019, 83(6): 1057-1063. DOI: 10.1007/s00280-019-03796-4.
|
| [32] |
Aftimos P, Rolfo C, Rottey S, et al. Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies[J]. Clin Cancer Res, 2017, 23(21): 6411-6420. DOI: 10.1158/1078-0432.CCR-17-0613.
|